The US FDA has recently approved ‘Dupilumab’ as the first treatment for nasal polyps in adults with chronic rhinosinusitis. The injectable significantly increases the ability to smell and reduces the need for oral steroids and nasal polyp surgery. The drug provides the first ever feasible treatment option for patients whose nasal polyps are not controlled with intranasal steroids. It also significantly lessens the need for nasal polyp surgery and oral steroids.
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a type of chronic condition where the sinuses and nasal passages are obstructed, thereby leading to difficulties in breathing, nasal congestion and discharge. It obstructs the upper airway in such a way to lessen the sense of smell and taste along with facial pressure. Many patients who suffer from CRSwNP could have severe asthma which can be very difficult to manage and…
